Nektar is not alone in this space and other TLR7/8 agonists have shown real promise as intratumoral therapies. The other Nektar agent is the modified IL-2 that looks like it may confer some benefit on top of PD-1. So, in all, this trial is about as good a trial to consider in the PD1 + X category."
- Posts: 11230
- Joined: Wed Jan 02, 2008 12:09 am
Melanoma International Foundation
Users browsing this forum: No registered users and 4 guests